EGFR and metastatic neoplasm: Future research should also take into account the potential of dose escalation to increase the effectiveness of existing treatment—taking into account the example of osimertinib dose escalation in CNS metastases, the mutation profile of both primary and metastatic tumors as a means to predict the response to targeted agents and the co-existence of EGFR mutations with other mutations or molecular traits that may alter the response to treatment.